Myeloproliferative Neoplasms (MPN)

- CNL/atypical CML
  - IRB#10262
    - Oral Ruxolitinib for CNL or atypical CML.
- Myelofibrosis
  - IRB#16363
    - Phase 2 INC8050465 plus Ruxolitinib
  - IRB#15836
    - Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation
- Systemic Mastocytosis
  - IRB#17899
    - Study Coming Soon

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php